Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
These melas serve as platforms to attract thousands of people to avail quality healthcare services along with essential medicines and diagnostic services
The initial courses of Lap. Hernia Masterclass will encompass commonly performed hernia procedures
Dr. Mansukh Mandaviya launches a quarterly report on AB-HWCs, Guidelines on Human resources for health, Public Health Management Cadre’ Guidance for implementation and Indian Public Health Standards Guidelines; interacts with healthcare workers from across the country
The minister exhorted the pharmaceutical sector to prepare a plan for the next 25 years
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
